7 results on '"Stone, Deborah L."'
Search Results
2. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
- Author
-
Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, and Goldbach-Mansky R
- Subjects
- Adolescent, Azetidines administration & dosage, Azetidines adverse effects, Child, Child, Preschool, Cohort Studies, Compassionate Use Trials, Female, Hereditary Autoinflammatory Diseases enzymology, Humans, Infant, Inflammation enzymology, Janus Kinase Inhibitors administration & dosage, Janus Kinase Inhibitors adverse effects, Male, Prospective Studies, Purines, Pyrazoles, Sulfonamides administration & dosage, Sulfonamides adverse effects, Treatment Outcome, Young Adult, Azetidines therapeutic use, Hereditary Autoinflammatory Diseases drug therapy, Hereditary Autoinflammatory Diseases immunology, Inflammation drug therapy, Inflammation immunology, Interferons antagonists & inhibitors, Interferons metabolism, Janus Kinase 1 antagonists & inhibitors, Janus Kinase 2 antagonists & inhibitors, Janus Kinase Inhibitors therapeutic use, Sulfonamides therapeutic use
- Abstract
Background: Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease., Methods: Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes-associated [STING-associated] vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access program. The patients underwent dose escalation, and the benefit was assessed by reductions in daily disease symptoms and corticosteroid requirement. Quality of life, organ inflammation, changes in IFN-induced biomarkers, and safety were longitudinally assessed., Results: Eighteen patients were treated for a mean duration of 3.0 years (1.5-4.9 years). The median daily symptom score decreased from 1.3 (interquartile range [IQR], 0.93-1.78) to 0.25 (IQR, 0.1-0.63) (P < 0.0001). In 14 patients receiving corticosteroids at baseline, daily prednisone doses decreased from 0.44 mg/kg/day (IQR, 0.31-1.09) to 0.11 mg/kg/day (IQR, 0.02-0.24) (P < 0.01), and 5 of 10 patients with CANDLE achieved lasting clinical remission. The patients' quality of life and height and bone mineral density Z-scores significantly improved, and their IFN biomarkers decreased. Three patients, two of whom had genetically undefined conditions, discontinued treatment because of lack of efficacy, and one CANDLE patient discontinued treatment because of BK viremia and azotemia. The most common adverse events were upper respiratory infections, gastroenteritis, and BK viruria and viremia., Conclusion: Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interferonopathies. Monitoring safety and efficacy is important in benefit-risk assessment., Trial Registration: ClinicalTrials.gov NCT01724580 and NCT02974595., Funding: This research was supported by the Intramural Research Program of the NIH, NIAID, and NIAMS. Baricitinib was provided by Eli Lilly and Company, which is the sponsor of the expanded access program for this drug.
- Published
- 2018
- Full Text
- View/download PDF
3. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
- Author
-
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgård U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, and Goldbach-Mansky R
- Subjects
- Autoimmune Diseases drug therapy, Base Sequence, Child, Female, Genes, Recessive, Homozygote, Humans, Infant, Infant, Newborn, Inflammation drug therapy, Inflammation genetics, Interleukin 1 Receptor Antagonist Protein deficiency, Interleukin 1 Receptor Antagonist Protein genetics, Interleukin-1 genetics, Interleukin-1 physiology, Interleukin-1beta antagonists & inhibitors, Male, Mutation, Pedigree, RNA, Messenger metabolism, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Autoimmune Diseases genetics, Inflammation immunology, Interleukin 1 Receptor Antagonist Protein therapeutic use, Receptors, Interleukin-1 antagonists & inhibitors
- Abstract
Background: Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone., Methods: We studied nine children from six families who had neonatal onset of sterile multifocal osteomyelitis, periostitis, and pustulosis. Response to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first patient prompted us to test for the presence of mutations and changes in proteins and their function in interleukin-1-pathway genes including IL1RN., Results: We identified homozygous mutations of IL1RN in nine affected children, from one family from Newfoundland, Canada, three families from The Netherlands, and one consanguineous family from Lebanon. A nonconsanguineous patient from Puerto Rico was homozygous for a genomic deletion that includes IL1RN and five other interleukin-1-family members. At least three of the mutations are founder mutations; heterozygous carriers were asymptomatic, with no cytokine abnormalities in vitro. The IL1RN mutations resulted in a truncated protein that is not secreted, thereby rendering cells hyperresponsive to interleukin-1beta stimulation. Patients treated with anakinra responded rapidly., Conclusions: We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote this autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN. The absence of interleukin-1-receptor antagonist allows unopposed action of interleukin-1, resulting in life-threatening systemic inflammation with skin and bone involvement. (ClinicalTrials.gov number, NCT00059748.), (2009 Massachusetts Medical Society)
- Published
- 2009
- Full Text
- View/download PDF
4. Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features.
- Author
-
Schwartz, Daniella Muallem, Kitakule, Moses M., Dizon, Brian L. P., Gutierrez-Huerta, Cristhian, Blackstone, Sarah A., Burma, Aarohan M., Son, Aran, Deuitch, Natalie, Rosenzweig, Sofia, Komarow, Hirsh, Stone, Deborah L., Jones, Anne, Nehrebecky, Michele, Hoffmann, Patrycja, Romeo, Tina, Almeida de Jesus, Adriana, Alehashemi, Sara, Garg, Megha, Torreggiani, Sofia, and Sanchez, Gina A. Montealegre
- Subjects
SKIN diseases ,CRYOPYRIN-associated periodic syndromes ,MONONUCLEAR leukocytes ,GROWTH factors ,CROSS-sectional method ,AUTOIMMUNE diseases ,HYDROLASES ,RESEARCH funding ,ALLERGIES ,AUTOINFLAMMATORY diseases - Abstract
Background: Monogenic autoinflammatory diseases (AID) are caused by mutations in innate immune genes. The effects of these mutations on allergic inflammation are unknown.Objectives: We investigated allergic, immunological and clinical phenotypes in FMF (familial Mediterranean fever), CAPS (cryopyrin-associated periodic syndrome), TRAPS (tumour necrosis factor receptor-associated periodic syndrome), HIDS (hyper-IgD syndrome), PAPA (pyogenic arthritis, pyoderma gangrenosum and acne), DADA2 (deficiency of adenosine deaminase 2), HA20 (haploinsufficiency of A20), CANDLE (chronic atypical neutrophilic dermatosis, lipodystrophy, elevated temperature) and SAVI (STING-associated vasculopathy of infancy).Methods: In this cross-sectional study, clinical data were assessed in 425 patients with AID using questionnaires and chart reviews. Comparator data were obtained from public databases. Peripheral blood mononuclear cells obtained from 55 patients were stimulated and CD4+ cytokine production assessed.Results: Clinical laboratory features of Type 2 immunity were elevated in CAPS but reduced in most AID, particularly DADA2. Physician-diagnosed allergic diseases were prevalent in multiple AID, including CAPS and DADA2. T helper 2 (Th2) cells were expanded in CAPS, TRAPS and HIDS; Th9 cells were expanded in HA20.Conclusions: CAPS is characterised by an enhanced Type 2 signature, whereas FMF and CANDLE are associated with reduced Type 2 responses. DADA2 is associated with reduced Type 2 responses but a high rate of physician-diagnosed allergy. Therefore, NLRP3-driven autoinflammation may promote Type 2 immunity, whereas AID like DADA2 may manifest clinical phenotypes that masquerade as allergic disorders. Further investigations are needed to determine the contribution of autoinflammation to allergic clinical and immunological phenotypes, to improve the treatment of patients with AID. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome.
- Author
-
Mistry, Pragnesh, Carmona-Rivera, Carmelo, Ombrello, Amanda K., Hoffmann, Patrycja, Seto, Nickie L., Jones, Anne, Stone, Deborah L., Naz, Faiza, Carlucci, Philip, Dell'Orso, Stefania, Gutierrez-Cruz, Gustavo, Hong-Wei Sun, Kastner, Daniel L., Aksentijevich, Ivona, Kaplan, Mariana J., and Sun, Hong-Wei
- Abstract
Objectives: Pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome is characterised by flares of sterile arthritis with neutrophil infiltrate and the overproduction of interleukin (IL)-1β. The purpose of this study was to elucidate the potential role of neutrophil subsets and neutrophil extracellular traps (NET) in the pathogenesis of PAPA.Methods: Neutrophils and low-density granulocytes (LDG) were quantified by flow cytometry. Circulating NETs were measured by ELISA and PAPA serum was tested for the ability to degrade NETs. The capacity of NETs from PAPA neutrophils to activate macrophages was assessed. Skin biopsies were analysed for NETs and neutrophil gene signatures.Results: Circulating LDGs are elevated in PAPA subjects. PAPA neutrophils and LDGs display enhanced NET formation compared with control neutrophils. PAPA sera exhibit impaired NET degradation and this is corrected with exogenous DNase1. Recombinant human IL-1β induces NET formation in PAPA neutrophils but not healthy control neutrophils. NET formation in healthy control neutrophils is induced by PAPA serum and this effect is inhibited by the IL-1 receptor antagonist, anakinra. NETs from PAPA neutrophils and LDGs stimulate IL-6 release in healthy control macrophages. NETs are detected in skin biopsies of patients with PAPA syndrome in association with increased tissue IL-1β, IL-8 and IL-17. Furthermore, LDG gene signatures are detected in PAPA skin.Conclusions: PAPA syndrome is characterised by an imbalance of NET formation and degradation that may enhance the half-life of these structures in vivo, promoting inflammation. Anakinra ameliorates NET formation in PAPA and this finding supports a role for IL-1 signalling in exacerbated neutrophil responses in this disease. The study also highlights other inflammatory pathways potentially pathogenic in PAPA, including IL-17 and IL-6, and these results may help guide new therapeutic approaches in this severe and often treatment-refractory condition. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
6. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease.
- Author
-
Aeschlimann, Florence A., Batu, Ezgi D., Canna, Scott W., Go, Ellen, Gül, Ahmet, Hoffmann, Patrycja, Leavis, Helen L., Ozen, Seza, Schwartz, Daniella M., Stone, Deborah L., van Royen-Kerkof, Annet, Kastner, Daniel L., Aksentijevich, Ivona, and Laxer, Ronald M.
- Subjects
IMMUNOSUPPRESSIVE agents ,COMPARATIVE studies ,GENETIC disorders ,INFLAMMATION ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,RESEARCH ,PHENOTYPES ,DNA-binding proteins ,EVALUATION research ,DISEASE progression - Abstract
Objectives: The association between mutations in TNFAIP3, encoding the NF-kB regulatory protein A20, and a new autoinflammatory disease has recently been recognised. This study aims at describing the clinical phenotypes and disease course of patients with A20 haploinsufficiency (HA20).Methods: Data for all cases from the initial publication, and additional cases identified through collaborations since, were collected using standardised data collection forms.Results: A total of 16 patients (13 female) from seven families with a genetic diagnosis of HA20 were included. The disease commonly manifested in early childhood (range: first week of life to 29 years of age). The main clinical symptoms were recurrent oral, genital and/or gastrointestinal ulcers (16/16), musculoskeletal (9/16) and gastrointestinal complaints (9/16), cutaneous lesions (8/16), episodic fever (7/16), and recurrent infections (7/16). Clinical phenotypes varied considerably, even within families. Relapsing-remitting disease course was most common, and one patient died. Laboratory abnormalities included elevated acute-phase reactants and fluctuating presence of various autoantibodies such as antinuclear antibodies (4/10 patients tested) and anti-dsDNA (2/5). Tissue biopsy of different sites revealed non-specific chronic inflammation (6/12 patients tested), findings consistent with class V lupus nephritis in one patient, and pustules and normal results in two patients each. All patients were treated: 4/16 received colchicine and 12/16 various immunosuppressive agents. Cytokine inhibitors effectively suppressed systemic inflammation in 7/9 patients.Conclusions: Early-onset recurrent oral, genital and/or gastrointestinal ulcers are the hallmark feature of HA20. Frequency and intensity of other clinical manifestations varied highly. Treatment regimens should be based on disease severity, and cytokine inhibitors are often required to control relapses. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes.
- Author
-
Sibley, Cailin H., Plass, Nikki, Snow, Joseph, Wiggs, Edythe A., Brewer, Carmen C., King, Kelly A., Zalewski, Christopher, Kim, H. Jeffrey, Bishop, Rachel, Hill, Suvimol, Paul, Scott M., Kicker, Patrick, Phillips, Zachary, Dolan, Joseph G., Widemann, Brigitte, Jayaprakash, Nalini, Pucino, Frank, Stone, Deborah L., Chapelle, Dawn, and Snyder, Christopher
- Subjects
AUDIOLOGY ,BLOOD testing ,C-reactive protein ,CONFIDENCE intervals ,DRUG side effects ,INFLAMMATION ,INTERLEUKINS ,MAGNETIC resonance imaging ,QUESTIONNAIRES ,RESEARCH funding ,STATISTICS ,T-test (Statistics) ,DATA analysis ,DATA analysis software ,DIARY (Literary form) ,DESCRIPTIVE statistics ,CHEMICAL inhibitors - Abstract
Objective Blocking interleukin-1 with anakinra in patients with the autoinflammatory syndrome neonatal-onset multisystem inflammatory disease (NOMID) reduces systemic and organ-specific inflammation. However, the impact of long-term treatment has not been established. This study was undertaken to evaluate the long-term effect of anakinra on clinical and laboratory outcomes and safety in patients with NOMID. Methods We conducted a cohort study of 26 NOMID patients ages 0.80-42.17 years who were followed up at the NIH and treated with anakinra 1-5 mg/kg/day for at least 36 months. Disease activity was assessed using daily diaries, questionnaires, and C-reactive protein level. Central nervous system (CNS) inflammation, hearing, vision, and safety were evaluated. Results Sustained improvements in diary scores, parent's/patient's and physician's global scores of disease activity, parent's/patient's pain scores, and inflammatory markers were observed (all P < 0.001 at 36 and 60 months). At 36 and 60 months, CNS inflammation was suppressed, with decreased cerebrospinal fluid white blood cell counts ( P = 0.0026 and P = 0.0076, respectively), albumin levels, and opening pressures ( P = 0.0012 and P < 0.001, respectively). Most patients showed stable or improved hearing. Cochlear enhancement on magnetic resonance imaging correlated with continued hearing loss. Visual acuity and peripheral vision were stable. Low optic nerve size correlated with poor visual field. Bony lesions progressed. Adverse events other than viral infections were rare, and all patients continued to receive the medication. Conclusion These findings indicate that anakinra provides sustained efficacy in the treatment of NOMID for up to 5 years, with the requirement of dose escalation. Damage progression in the CNS, ear, and eye, but not bone, is preventable. Anakinra is well tolerated overall. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.